Latest News for: alks

Edit

EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis (ALK-Abelló A/S)

Public Technologies 15 Jun 2026
ALK announced ... Flora Beiche-Scholz, EVP Commercial Operations Europe, ALK says. ... About ALK. ALK is a global specialty pharmaceutical company focused on allergy ... ALK B). Visit us at www.alk.net ... ALK ... ALK.
Edit

Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap (ALK-Abelló A/S)

Public Technologies 11 Jun 2026
Judit Nyirady, Senior VP, Global Chief Medical Office, ALK ... These data reinforce ALK's commitment to ensuring that everyone at risk of anaphylaxis has a treatment they will actually carry and use." ... About ALK ... ALK B). Visit us at www.alk.net ... ALK.
Edit

CUHK co-led landmark global study shows over half of advanced ALK-positive lung cancer patients stay progression-free at seven years Revealing potential to transform specific oncogene-driven lung cancer into a chronic disease (The Chinese University of Hong Kong)

Public Technologies 10 Jun 2026
CUHK co-led landmark global study shows over half of advanced ALK-positive lung cancer patients stay progression-free at seven years ... A patient, Mr Ng, shares that he was diagnosed with advanced ALK-positive lung cancer in 2022 at the age of 58.
Edit

Lung Cancer Research Foundation Announces Request for Proposals Open for ALK-Positive Lung Cancer Research Grant

PR Newswire 09 Jun 2026
Research Award Focused on Accelerating Treatment Options for People with ALK-Positive Lung Cancer ... ALK-positive Research Grant RFP ... This led to the development of targeted drugs called ALK inhibitors, the first of which was FDA-approved in 2011.
Edit

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 ...

Nasdaq Globe Newswire 04 Jun 2026
At the Annual Congress of the European Academy of Allergy ...
Edit

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff (ALK-Abelló A/S)

Public Technologies 01 Jun 2026
2026-06-01 21.20.14 CEST ALK-Abelló - Managers' Transactions Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff. ALK (ALKB.DC / Nasdaq Copenhagen. ALK B).
Edit

Report on transactions with ALK-Abell� A/S B shares and associated securities by managerial staff

Nasdaq Globe Newswire 01 Jun 2026
ALK (ALKB.DC / Nasdaq Copenhagen. ALK B). In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abell� A/S shall report the following transactions by managerial staff ... .
Edit

ALK to present at the Jefferies Global Healthcare Conference in New York

Nasdaq Globe Newswire 29 May 2026
ALK (ALKB.DC / Nasdaq Copenhagen. ALK B) today announced that ...
Edit

Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

PR Newswire 27 May 2026
New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026.
Edit

Funding from Patients, Caregivers, Foundations and Industry Partners Fuels ALK-positive Research

PR Newswire 19 May 2026
Funding ALK positive lung cancer research. More than 500,000 people worldwide are currently living with ALK-positive NSCLC and often affects younger adults with no history of tobacco use or other known risk factors.
Edit

Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors (Chugai Pharmaceutical Co Ltd)

Public Technologies 18 May 2026
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors ... alectinib), an anti-cancer agent/ALK inhibitor for ALK fusion gene-positive solid tumors.
Edit

Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients (Chugai Pharmaceutical Co Ltd)

Public Technologies 18 May 2026
Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients ... alectinib) for advanced or recurrent ALK fusion gene-positive solid tumors, including pediatric patients.
Edit

ALKS Q1 2026 Earnings Slides FINAL (Alkermes plc)

Public Technologies 05 May 2026
). First Quarter 2026. Financial Results & Business Update. May 5, 2026. Q1 2026 Financial and Operational Performance. Q1 2026 Financial Results Summary. $306.5. $392.9. In millions. Q1 2025. Q1 2026. Total Revenue. $0.13. ($0.40). Q1 2025. Q1 2026 ... Diluted ... - ... .
Edit

ALKS Q1 2026 Earnings Call Prepared Remarks FINAL (Alkermes plc)

Public Technologies 05 May 2026
... phase 1 studies and development efforts for our next orexin 2 receptor agonist candidates, ALKS 7290 and ALKS 4510 ... We are doing so with two new molecules from our portfolio, ALKS 7290 and ALKS 4510.
Edit

Presentation (ALK-Abelló A/S)

Public Technologies 04 May 2026
First proof-of-concept for ALK's tablet technology in food allergy ... per.plotnikof@alk.net; marine.arzic@alk.net. ALK markets a diversified portfolio of products, including allergy immunotherapy (AIT) tablets,.

Article Search

tools
×
×
×
×